Trialogics, based in Delaware, has established an office in London to help meet ongoing clinical trial demands in the United Kingdom.
"As our international business increases, especially the supply and management of devices, we need to expand our international presence to meet those needs as efficiently as possible," Trialogics Chief Executive Officer Chris Gropp said. "Expanding our integrated logistics with our other services such as eConsent, IRT (RTSM), and eCOA gives our clients the necessary data to monitor sites, subjects, timelines and expenses."
Trialogics specializes in clinical trial software and services and provides eConsent, IRT (RTSM), and eCOA. Its new office opening forms part of the company’s efforts to expand its remote device management capabilities and service catalog in general.
The London-based office will take on some of the weight borne by Trialogics' Rome-based office, which oversaw the needs of sites across Europe.
The company plans to open an additional office in Sydney, Australia, in mid-2024 to fulfill the needs of clients based in the Asia-Pacific region.
The company deploys Samsung devices with mobile data plans to clinical trial sites, which then use the devices to access Trialogics' system and other clinical trial services. The devices also allow the sites to manage patients and upload data to secure cloud storage.
“Sites also assign devices to patients to complete questionnaires and diaries and capture additional data from other mobile devices,” the press release explains. “The data is transmitted to a central database associated with the ongoing clinical trial, allowing clinicians to review the data in real-time.”
"Since our founding, we have recognized the need for better mobile device management in the industry. Trialogics has built this technology while focusing on the security of the devices and providing exceptional clinical trial services," Gropp said.